Safety and Efficacy Profile of CSE-1034 as a Prolonged De-escalation Therapy in Prosthetic Joint Infection: A Case Report

Main Article Content

Prachee Sathe
Pankaj Mandale


Background: Although rare, infection is considered to be most dreadful of the prosthetic related complications resulting in repeated surgical intervention, extended hospitalization or sometimes in loss of implant or permanent disability if not treated promptly. Poor treatment outcome associated with prosthetic joint infections (PJIs) could be partly attributed to rise in anti-microbial resistance among the causative agents.

Case Presentation: This is a first reported case of ceftriaxone + sulbactam + ethylenediaminetetraacetic acid (CSE 1034) being used as an de-escalation therapy for more than 24 days with good safety and efficacy outcome in a 78 year male patient with PJI associated with hip replacement surgery, treated initially with meropenem and colistin followed by prolonged de-escalation therapy (24 days).

Conclusions: In clinically complicated cases of deep infections where prolonged use of last resort antibiotics is used, CSE-1034 can be considered as a safe, efficacious and economical de-escalating antibiotic to complete the treatment course and prevent recurrence of infection, especially in PJI.

De-escalation therapy, prosthetic joint infections, CSE-1034, antibiotics.

Article Details

How to Cite
Sathe, P., & Mandale, P. (2019). Safety and Efficacy Profile of CSE-1034 as a Prolonged De-escalation Therapy in Prosthetic Joint Infection: A Case Report. Journal of Advances in Medicine and Medical Research, 30(7), 1-4.
Original Research Article


Lima ALL, Oliveira PR, Carvalho VC, Saconi ES, Cabrita HB, Rodrigues MB. Interdiscip Perspect Infect Dis. 2013; 542796.

Kunutsor SK, Beswick AD, Peters TJ, Gooberman-Hill R, Whitehouse MR, Blom AW, Moore AJ. Health care needs and support for patients undergoing treatment for prosthetic joint infection following hip or knee arthroplasty: A systematic review. PloS One. 2017;12(1).

Masters JPM, Smith NA, Foguet P, Reed M, Parsons H, Sprowson AP. A systematic review of the evidence for single stage and two stage revision of infected knee replacement. BMC Musculoskelet Disord. 2013;14:222.

Minassian AM, Osmon DR, Berendt AR. Clinical guidelines in the management of prosthetic joint infection. J Antimicrob Chemother. Journal of Antimicrobial Chemotherapy. 2014;69 (Suppl_1):i29–i35.

de Sanctis J, Teixeira L, van Duin D, Odio C, Hall G, Tomford JW, Perez F, Rudin SD, Bonomo RA, Barsoum WK, Joyce M, Krebs V, Schmitt S. Complex prosthetic joint infections due to carbapenemase-producing Klebsiella pneumoniae: A unique challenge in the era of untreatable infections. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2014;25: 73–78.

Legout L, Senneville E. Periprosthetic joint infections: Clinical and bench research. The Scientific World Journal. 2013;17.
Article ID: 549091

Tande AJ, Patel R. Prosthetic joint infection. Clin Microbiol Rev. 2014;27: 302–345.

Prokuski L. Prophylactic antibiotics in orthopaedic surgery. J Am Acad Orthop Surg. 2008;16:283–293.

Huang R, Cai GQ, Zhang JH, Liu FX, Ma JQ, Liu H, Nie XM, Gui R. Meropenem-induced immune thrombocytopenia and the diagnostic process of laboratory testing. Transfusion (Paris). 2017;57(11): 2715-2719.

Chaudhary M, Mir MA, Ayub SG. Safety and efficacy of a novel drug elores (ceftriaxone + sulbactam + disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study. Braz J Infect Dis. 2017;21:408–417.

Vishal Bhambri. Significance of cse-1034 (Elores) in treatment of urinary tract infections due to multi-drug resistant extended spectrum beta-lactamases positive Escherichia coli. Asian J Pharm Clin Res. 2016;9(6):12-13.

Sathe P, Maddani S, Kulkarni S, Munshi N. Management of ventilator associated pneumonia with a new antibiotic adjuvant entity (ceftriaxone + sulbactam + disodium edetate) - A novel approach to spare carbapenems. J Crit Care. 2017;41:145–149.